Medline Inc. Class A common stock
Here’s whether Medline Inc. Class A common stock (MDLN) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: above the 50-day MA (medium-term momentum positive); RSI 36 — healthy momentum range. Concerns: 50-day MA is falling (-1.68% over 10 days); 3-month momentum negative (-13.4%). Currently 23.8% off its 52-week high. Score: +0/7.
MDLN is trading below its 200-day MA (—) — a key warning sign the longer-term trend is under pressure. An RSI of 36.2 sits in the neutral zone — momentum is neither stretched nor exhausted. With ~7 months of trading history, the return since first available bar is -5.5%. The current 23.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.